BBIO · NASDAQ · STOCK
BridgeBio Pharma, Inc.
$83.71
52W $46.81 – $93.42
65/100
$16.39B
-23.4
0.98
Is BBIO Bullish or Bearish?
Mixed.
Innellis AI committee rates BridgeBio Pharma, Inc. (BBIO) Insufficient Data with a composite score of 65/100
, based on 3 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
No threshold can be published for BBIO. The committee has not produced a scored recommendation, so there is no line for it to cross. Innellis does not infer one.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
3
Conviction
Low Data
Sector Rank
Top 16%
of 192 Healthcare peers
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
56.9
Neutral
MACD Histogram
-0.292
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$62.84
Resistance
$84.40
Bollinger %B
0.68
Inside Bands
Price vs Moving Averages
EMA 9
$83.16
Above
EMA 21
$81.90
Above
EMA 50
$78.25
Above
EMA 200
$69.73
Above
Fundamental Analysis
Valuation
100
Profitability
50
Financial Health
68
Cash Flow
15
Valuation
P/E Ratio
-23.4×
P/B Ratio
-6.52×
PEG Ratio
-1.81
Dividend Yield
0.00%
52W High
$93.42
52W Low
$46.81
Quality & Growth
ROE
3512.1%
ROA
-7791.5%
Gross Margin
9314.1%
Operating Margin
-7855.5%
Revenue Growth YoY
—
Debt / Equity
-0.99
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -23.4 (inexpensive relative to a 15-40x range); Price-to-book of -6.5x; PEG ratio of -1.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 35.1%; Return on assets of -77.9%; Net margin of -100.6%; Gross margin of 93.1%; Current ratio of 1.23 (tight short-term liquidity); Debt-to-equity of -0.99; Free cash flow per share is negative (-3.02); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full BBIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →